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Background. Individuals infected with human immunodeﬁciency virus (HIV) have increased risk of
cardiovascular events. It is unknown whether T cell activation and senescence, 2 immunologic sequelae of HIV
infection, are associated with vascular disease among HIV-infected adults.
Methods. T cell phenotyping and carotid ultrasound were assessed among 115 HIV-infected women and 43
age- and race/ethnicity-matched HIV-uninfected controls participating in the Women’s Interagency HIV Study.
Multivariate analyses were used to assess the association of T cell activation (CD38
1HLA-DR
1) and senescence
(CD28
2CD57
1) with subclinical carotid artery disease.
Results. Compared with HIV-uninfected women, frequencies of CD4
1CD38
1HLA-DR
1, CD8
1CD38
1HLA-
DR
1, and CD8
1CD28
2CD57
1 T cells were higher among HIV-infected women, including those who achieved viral
suppression while receiving antiretroviral treatment. Among HIV-infected women, adjusted for age, antiretroviral
medications, and viral load, higher frequencies of activated CD4
1 and CD8
1 T cells and immunosenescent CD8
1
T cells were associated with increased prevalence of carotid artery lesions (prevalence ratiolesions associated with
activated CD4
1 T cells, 1.6 per SD [95% conﬁdence interval {CI}, 1.1–2.2]; P 5 .02; prevalence ratiolesions associated
with activated CD8
1 T cells, 2.0 per SD [95% CI, 1.2–3.3]; P , .01; prevalence ratiolesions associated with senescent
CD8
1 T cells, 1.9 per SD [95% CI, 1.1–3.1]; P 5 .01).
Conclusions. HIV-associated T cell changes are associated with subclinical carotid artery abnormalities, which
may be observed even among those patients achieving viral suppression with effective antiretroviral therapy.
As compared with control individuals without human
immunodeﬁciency virus (HIV) infection, HIV-infected
patients have increased risk of acute cardiovascular
disease (CVD) events including myocardial infarction
[1] and advanced subclinical vascular disease [2]. The
CVD risk associated with HIV infection appears to be
partially attenuated by antiretroviral treatment, since
treatmentinterruptionincreases short-termriskofCVD
events [3]. Although effective HIV therapy appears to
reduce the risk of CVD, it may not fully reverse HIV-
associated vascular risk, and long-term exposure to HIV
therapy may have direct adverse effects on CVD [4].
The mechanism for increased CVD risk in anti-
retroviral-treated and untreated HIV infection is likely
multifactorial, involving pathways related to traditional
vascular risk factors and antiretroviral drug toxicities.
Chronic inﬂammation, which is a well-accepted CVD
risk factor in the non-HIV setting, may also be impor-
tant. Many markers of inﬂammation, including T cell
activation as deﬁned by co-expression of CD38 and
HLA-DR, are markedly elevated in individuals with
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452 d JID 2011:203 (15 February) d Kaplan et al.untreated HIV infection and are only partially reversed by
effective combination antiretroviral therapy [5, 6]. The fre-
quency of activated CD8
1 T cells predicts the risk of disease
progression independent of other factors in untreated HIV
infection [7] and is consistently associated with immunologic
and perhaps clinical outcomes in the context of antiretroviral-
treated infection [6]. The role of activated T cells and their
inﬂammatory products in atherosclerosis has been well
studied [8], although whether vascular changes in HIV-in-
fected patients are inﬂuenced by systemic T cell activation
remains uncertain.
There is a growing body of literature suggesting that chronic
viral infections cause accelerated aging of the immune system
(called ‘‘immunosenescence’’). For example, cytomegalovirus
(CMV) infection is associated with oligoclonal expansion of
terminally differentiated T cells, decreased T cell repertoire,
lower T cell proliferation rates, and increased levels of a number
of inﬂammatory markers [9]. Untreated HIV infection produces
a number of these same phenotypic and functional changes to
the immune system [10]. More recently, evidence has emerged to
suggest that immune senescence driven by responses to chronic
infection may play a role in heart and vascular diseases [11].
Given the evidence that HIV infection is associated with in-
creased levels of immune activation, inﬂammation, and im-
munosenescence, we conducted a study to address the hypothesis
that these pathways mediate the association of HIV infection with
vascular disease. Archived specimens from a well-characterized
longitudinal US cohort of HIV-infected and HIV-uninfected
women were used to measure cell surface expression of CD38,
HLA-DR, CD28, and CD57 on CD4
1 and CD8
1 T cells. We
then related activation (CD38
1HLA-DR
1) and senescent
(CD28
2CD57
1) T cell subsets with subclinical vascular disease as
assessed by B-mode carotid artery ultrasound.
METHODS
Study Population
This study was conducted among participants in the Women’s
Interagency HIV Study (WIHS), a prospective multicenter
study. Participants were recruited in 2 waves (in 1994–1995 and
2001–2002) and completed study visits every 6 months. In April
2004, a carotid ultrasound substudy was initiated which in-
cluded B-mode ultrasound imaging of the carotid arteries. For
the present investigation, we conducted T cell phenotyping
among 115 HIV-infected women who were >40 years of age at
the time of their carotid artery ultrasound scan and free of
clinical vascular disease. A group of HIV-uninfected women
(n 5 43) was also selected who were frequency-matched to the
HIV-infected individuals by age (65 years) and race/ethnicity.
The HIV-infected and HIV-uninfected groups had comparable
demographic and socioeconomic characteristics and were
recruited using similar methods. Institutional review board
approval and informed consent were obtained.
Carotid Artery Ultrasound
High-resolution B-mode carotid artery ultrasound was used to
image the right common carotid artery, internal carotid artery,
and carotidbifurcation [12]. Right distalcommon carotid artery
intima-media thickness (cIMT) was measured. The presence of
carotid lesions was deﬁned as a focal intima-media thickness of
.1.5 mm in any of the imaged segments. Standardized carotid
artery ultrasound images were centrally measured by automated
computerized edge detection by use of a software package de-
veloped in-house (Prowin patent, 2005, 2006).
Assays
HIV infection was determined via serologic testing using en-
zyme-linked immunosorbent assay (ELISA) and conﬁrmed us-
ing Western blot assays. Plasma HIV RNA levels were quantiﬁed
using nucleic-acid-sequence-based ampliﬁcation commercial
assays with a lower limit of quantiﬁcation of 80 copies/mL
(bioMe ´rieux), and total peripheral CD4
1 Tc e l lc o u n t sw e r e
measured with standard ﬂow cytometric methods. T cell acti-
vation and senescence were measured by immunophenotyping
performed at the University of California, San Francisco, Core
Immunology Laboratory, using methods that have been opti-
mized and validated for frozen peripheral blood mononuclear
cells (PBMCs). Cryopreserved PBMCs were rapidly thawed in
warm medium, washed, stained with Viacount (Millipore), and
run on a Guava PCA (Millipore) to determine cell number and
viability. Samples with viability of ,40% were not analyzed.
PBMCs were stained with aqua amine reactive dye (Invitrogen)
to exclude nonviable cells and for surface expression of CD3,
CD28 (BD Pharmingen), CD4, CD38, HLA-DR (BD Bio-
sciences), CD8 (Invitrogen), and CD57 (Biolegend). Stained
cells were run on a customized BD LSR II and data analyzed
using FlowJo software, version 8.8.4 (Tree Star) to quantitate
CD4
1 and CD8
1 T cells expressing activation (CD38 and HLA-
DR) and senescence (CD28
2 and CD57
1) markers (Figure 1).
Data on CD38
1HLA-DR
1 and CD28
2CD57
1 subsets were ex-
pressed as the percentage of T cells expressing these markers.
Clinical Variables
Key cardiovascular and HIV-related covariates were obtained by
self-report and direct measurements. We deﬁned highly active
antiretroviral therapy (HAART) in accordance with US De-
partment of Health and Human Services guidelines.
Data Analyses
HIV-infected women were stratiﬁed as (1) untreated, (2)
HAART-treated aviremic, or (3) treated with detectable viremia.
Primary analyses examined carotid artery lesions and cIMT in
relation to contemporaneous measures of T cell activation
(CD38
1HLA-DR
1) and T cell senescence (CD28
2CD57
1).
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sion prevalence and linear regression models for cIMT. Initial
analyses included adjustment for age and current use of protease
inhibitors, nonnucleoside reverse-transcriptase inhibitors, and
nucleoside reverse-transcriptase inhibitors. Additional nested
models featured adjustment for concurrent viral load. Further
adjustment for cumulative exposure to HIV medications and
proportion of prior study visits with HIV RNA level of .4000
copies/mL had no effect. We also performed adjustment for
CD4
1 T cell count and ratio of CD4
1 T cells to CD8
1 Tc e l l s .
Subsequent models examined the potential confounding effects
of cardiovascular risk factors, socioeconomic factors, and use of
cigarettes, alcohol, and injection drugs. To assess whether the
nature of associations between T cell phenotypes and subclinical
carotid artery disease was modiﬁed by HIV infection, we
included interaction terms in models that included both HIV-
infected and HIV-uninfected groups and also conducted
analyses stratiﬁed by presence or absence of HIV infection.
RESULTS
HIV-infected women (n 5 115) and HIV-uninfected women
(n 5 43) were comparable in age (mean age of HIV-infected
women, 46years;mean age ofHIV-uninfectedwomen, 47years)
and race/ethnicity (63% and 67% of HIV-infected and HIV-
uninfected women were African American, respectively, and
28% and 23% of HIV-infected and HIV-uninfected women
were Hispanic, respectively) (Table 1). Among HIV-infected
women, 36% were not currently receiving antiretroviral treat-
ment, 39% were treated and had detectable viremia, and 25%
were treated and had undetectable viremia.
As compared with the overall WIHS cohort, the HIV-infected
women in our study were slightly younger, were less likely to be
non-Hispanic white, and had higher current viral load, but they
did not otherwise differ signiﬁcantly (P , .05) on variables
shown in Table 1.
T Cell Activation Markers
Compared with HIV-uninfected women, HIV-infected women
had markedly higher levels of CD4
1 and CD8
1 T cell activation
(P , .01) (Table 1 and Figure 2). These differences remained
signiﬁcant when we restricted the HIV-infected group to those
who were treated with HAART and had achieved viral sup-
pression. Correlates of higher T cell activation included race/
ethnicity, lower high-density lipoprotein cholesterol level, lower
CD4
1 T cell count, lower ratio of CD4
1 T cells to CD8
1 Tc e l l s ,
and higher viral load (Table 2).
T Cell Senescence Markers
In comparison with HIV-uninfected controls, the percentage
of CD8
1 T cells with an immunosenescent phenotype
(CD28
2CD57
1) was increased among the HIV-infected
women (P , .01) (Table 1 and Figure 2). This difference
persisted even among HIV-infected women who were re-
ceiving HAART and who had undetectable HIV RNA levels.
Correlates of CD8
1CD28
2CD57
1 T cells included race/eth-
nicity, smoking, and high-density lipoprotein cholesterol but
not CD4
1 T cell count or plasma HIV RNA level (Table 2).
CD38
1HLA-DR
1 T Cells and Subclinical Carotid Artery Disease
Among the group of HIV-infected women, 19 had >1c a r o t i d
lesions whereas 96 had no carotid lesions. HIV-infected women
with carotid lesions had a signiﬁcantly higher percentage of
CD4
1 T cells expressing activation markers (CD38
1HLA-DR
1)
than those HIV-infected women without carotid lesions (P 5
.02) (Figure 3). The percentage of CD8
1 T cells expressing ac-
tivation markers was also higher in HIV-infected women with
lesions than that among HIV-infected women without lesions
(P 5 .04) (Figure 3).
In adjusted models, among HIV-infected women, the prev-
alence of carotid lesions was directly associated with the per-
centage of CD4
1 and CD8
1 T cells expressing activation
markers. Adjusted for age and antiretroviral medication use, the
prevalence ratiolesions was 1.6 per SD change in the percentage of
CD4
1CD38
1HLA-DR
1 T cells (95% conﬁdence interval [CI],
1.1–2.2; P 5 .02), and the prevalence ratiolesions was 2.0 per SD
change in the percentage of CD8
1CD38
1HLA-DR
1 Tc e l l s
(95% CI, 1.2–3.3; P , .01) (Table 3). This association persisted
Figure 1. Expression of activation (CD38 and HLA-DR) and senescence
(CD57 and CD28) markers on CD4
1 and CD8
1 T cells. Representative
fluorescence-activated cell-sorting plots showing gating of T cells to
define CD4
1 and CD8
1 T cells (A), activation markers to define CD38
1
HLA-DR
1 T cells (B), and senescent markers to define CD28
2CD57
1
T cells (C). Data were compensated and analyzed using FlowJo software
(Treestar). Standard lymphocyte and singlet gates were drawn to exclude
debris, monocytes, and doublets. Dead cells were excluded by gating on
aqua amine reactive dye–negative cells, and total Tcells were defined by
CD3
1 staining. Fluorescence-minus-1 controls were used to set T cell
subpopulation gates. The mean peripheral blood mononuclear cell
viability was 75.0% in human immunodeficiency virus (HIV)–infected
women and 77.5% in HIV-uninfected women.
454 d JID 2011:203 (15 February) d Kaplan et al.Table 1. Characteristics of Human Immunodeficiency Virus (HIV)–Infected and HIV-Uninfected Women in the Women's Interagency HIV Study
HIV-infected women
HIV-uninfected
women
Treated
viremic Untreated
Treated
viremic All
P, HIV-uninfected
vs all HIV-infected
women
P across HIV-uninfected
and 3 HIV-infected
groups
(N 5 43) (N 5 29) (N 5 41) (N 5 45) (N 5 115)
Characteristics Median/% IQR Median/% IQR Median/% IQR Median/% IQR Median/% IQR
Age, years 47 8 45 5 47 8 47 7 46 6 .91 .34
Laboratory variables
CD4
1CD38
1DR
1 T cells, % 2.5 1.5 5 3.8 7.9 8.5 11.7 13.3 7.7 9.4 ,.01 ,.01
CD8
1CD38
1DR
1 T cells, % 7.3 8.9 15.1 11.7 34 19.3 31.3 21.8 28.9 23.6 ,.01 ,.01
CD4
1CD28
2CD57
1 T cells, % 1.8 4.4 1.8 4.7 2.9 5.6 3.1 9.4 2.5 5.9 .07 .16
CD8
1CD28
2CD57
1 T cells, % 22.7 27.3 30.2 16 37.3 21.9 36.9 19.5 35.8 21.7 ,.01 ,.01
Current viral load, copies/mL NA . 80 0 4050 25,575 5500 20,680 1200 15,920 NA ,.01
Peak viral load, 31000 copies/mL NA . 110 330 24 83.6 160 343 60 305 NA ,.01
Current CD4 cell count, cells/lL 965 486 577 298 389 311 251 315 379 357 ,.01 ,.01
Nadir CD4 cell count, cells/lL 782 236 196 242 327 297 151 177 209 236 ,.01 ,.01
CD4/CD8 ratio of .1, % 100 . 31 . 12 . 9 . 16 . ,.01 ,.01
LDL-C level, mg/dL 104 37 99 22 93 46 92 36 97 33 .23 .18
HDL-C level, mg/dL 56 20 50 33 40 26 45 18 45 24 ,.01 ,.01
LDL-C level of .160 mg/dL, % 8 . 4 . 0 . 5 . 3 . .18 .39
HDL-C level of ,40 mg/dL, % 18 . 39 . 53 . 37 . 43 . ,.01 .02
Clinical variables
BMI, kg/m
2 29 12 26 6 28 6 26 7 27 6 .07 .16
BMI categories, % ,25 26 . 34 . 28 . 34 . 32 . .05 .33
25–30 26 . 38 . 45 . 37 . 40 .
.30 49 . 28 . 28 . 30 . 28 .
Weight, kg 80 31 73 16 78 22 67 27 73 22 .06 .11
Antiretroviral drugs
Duration of HAART use, years NA . 7 3 657373 N A . 0 6
No. of PIs used (current),
a %0 N A . 38 . NA . 24 . 55 . NA .42
1N A . 34 .. . 48 . 27 .
2N A . 28 .. . 28 . 18 .
Duration of PI use, years NA . 3.2 2.9 NA . 3.1 4.1 2.5 4.2 NA .94
NRTI use (current), % NA . 100 . NA . 98 . 63 . NA .42
Duration of NRTI use, years NA . 7.5 3.9 NA . 7.3 3.9 6 6.8 NA .50
NNRTI use (current), % NA . 52 . NA . 27 . 23 . NA .03
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HIV-infected women
HIV-uninfected
women
Treated
viremic Untreated
Treated
viremic All
P, HIV-uninfected
vs all HIV-infected
women
P across HIV-uninfected
and 3 HIV-infected
groups
(N 5 43) (N 5 29) (N 5 41) (N 5 45) (N 5 115)
Characteristics Median/% IQR Median/% IQR Median/% IQR Median/% IQR Median/% IQR
Duration of NNRTI use, years NA . 1.7 2.4 NA . .6 1.7 .3 2.4 NA .07
Adherence to antiretroviral drugs,
b %N A . 90 . NA . 72 . 77 . NA .03
Abacavir use, % NA . 21 . NA . 22 . 14 . NA .88
CVD risk factors
c
History of diabetes, % 33 . 17 . 15 . 31 . 22 . .15 .15
Diabetes medication use, % 16 . 0 . 7 . 9 . 6 . .046 .12
Lipid-lowering drug use, % 2 . 10 . 5 . 7 . 7 . .26 .53
Family history of CAD, % 13 . 12 . 29 . 15 . 19 . .41 .20
Hypertension, % 44 . 38 . 39 . 42 . 40 . .63 .94
Hepatitis C antibody positive, % 40 . 41 . 44 . 59 . 49 . .30 .32
Current smoking, % 70 . 34 . 49 . 57 . 48 . .01 .17
Race, % Other 9 . 14 . 2 . 11 . 8 . .85 .37
Hispanic 23 . 31 . 27 . 26 . 28 .
African American 67 . 55 . 71 . 63 . 63 .
NOTE. P values were derived using the Kruskal-Wallis test for continuous variables and v
2 test for categorical variables. BMI, body mass index; CAD, coronary artery disease; CVD, cardiovascular disease; HAART, highly
active antiretroviral therapy; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; NA, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI,
nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a PI use includes any use of ritonavir.
b Adherence was deﬁned by self-report as taking .95% of the prescribed dose.
c Hypertension was deﬁned as systolic blood pressure of >140 mm Hg, diastolic blood pressure of >90 mm Hg, or prior diagnosis of hypertension. Dyslipidemia was deﬁned as LDL-C level of .160 mg/dL or HDL-C
level of ,40 mg/dL. Diabetes was deﬁned as fasting plasma glucose level of .126 mg/dL or prior diagnosis of diabetes mellitus with or without the use of antidiabetic medications. Family history of coronary disease was
deﬁned as a female ﬁrst-degree relative with myocardial infarction or angina before age 65 or male ﬁrst-degree relative with myocardial infarction or angina before age 55.
4
5
6
d
J
I
D
2
0
1
1
:
2
0
3
(
1
5
F
e
b
r
u
a
r
y
)
d
K
a
p
l
a
n
e
t
a
l
.after adjustment for viral load and other potential confounders.
The association of CD4
1 T cell activation with carotid lesions
was attenuated after further adjustment for CD4
1 Tc e l lc o u n t
(adjusted prevalence ratiolesions, 1.1; 95% CI, .6–2.1) and after
adjustment for the ratio of CD4
1 T cells to CD8
1 T cells (ad-
justed prevalence ratiolesions, 1.5; 95% CI, .8–2.6). In contrast,
the association between CD8
1 T cell activation and carotid le-
sions remainedafter adjustment for CD4
1 T cellcountandratio
of CD4
1 T cells to CD8
1 Tc e l l s .
In contrast to the ﬁndings among HIV-infected women, we
did not observe an association between T cell activation and
increased prevalence of carotid lesions among HIV-uninfected
women (Figure 3). Models that included interaction terms
provided evidence of effect modiﬁcation by HIV status, such
thathigherlevelsofTcellactivationwereassociatedwithcarotid
lesions intheHIV-infected group but not inthe HIV-uninfected
group (signiﬁcance tests for interaction, P 5 .06 for CD4
1 Tc e l l
activation and P 5 .02 for CD8
1 T cell activation).
CD28
2CD57
1 T Cells and Subclinical Carotid Artery Disease
Among HIV-infected women, unadjusted analyses showed
a higher frequency of CD8
1CD28
2CD57
1 T cells in those with
carotid lesions than in those without carotid lesions (P 5 .03)
(Figure 3). After adjustment for age and use of antiretroviral
medications, the prevalence ratiolesions for each SD change in the
percentage of CD8
1CD28
2CD57
1 T cells was 1.9 (95% CI, 1.1–
3.1; P 5 .01) (Table 3). This signiﬁcant association persisted
after further adjustment for CD4
1 T cell count, ratio of CD4
1
Tc e l l st oC D 8
1 T cells, viral load, and other potential con-
founders. There were no differences in the frequency of CD4
1
CD28
2CD57
1 T cells between those with and those without
carotid lesions (Figure 3; Table 3). When we repeated the analysis
using CD28
2 alone rather than CD28
2CD57
1 to deﬁne T cell
subsets, there was an association of CD8
1CD28
2 Tc e l l sb u tn o t
CD4
1CD28
2 T cells with carotid lesions (data not shown).
Models that included interaction terms were consistent with
the hypothesis that higher levels of CD8
1 T cell senescence were
associated with carotid lesions in the HIV-infected group but
not in the HIV-uninfected group (signiﬁcance test for interac-
tion, P 5 .009).
In contrast to the ﬁndings for the outcome of carotid lesions,
cIMT measurements were not associated with T cell activation
or senescence markers in either HIV- infected women (Table 3)
or HIV-uninfected women (data not shown).
Multivariate Analyses of T Cell Phenotypes Associated With
Subclinical Carotid Artery Disease
When entered together into a multivariate model, both CD8
1
T cell activation and CD8
1 T cell senescence remained signiﬁ-
cant or borderline signiﬁcant in their associations with carotid
Figure 2. Tcell activation (CD38
1HLA-DR
1) and senescence (CD28
2CD57
1) among 115 human immunodeficiency virus (HIV)–infected women and 43
HIV-uninfected women. HIV-infected women include 41 who were not receiving antiretroviral therapy at the time of the study (Untreated), 29 who were
receiving highly active antiretroviral therapy and had no detectable plasma HIV (Aviremic), and 45 who were treated and had detectable plasma HIV
(Viremic). P ,.01 (Kruskal-Wallis test) for CD4
1 Tcell activation, CD8
1 Tcell activation, and CD8
1 Tcell senescence in comparing the HIV-infected group
with the HIV-uninfected group. For CD4
1 T cell senescence, P 5 .07 in comparing the HIV-infected group with the HIV-uninfected group.
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1HLA-DR
1 (Activated) T Cells and CD28
2CD57
1 (Senescent) T Cells Among Women With Human Immunodeficiency Virus (HIV)
Infection
Percentage of CD4
1
CD38
1DR
1 T cells
Percentage of CD8
1
CD38
1DR
1 T cells
Percentage of CD4
1CD28
2
CD57
1 T cells
Percentage of CD8
1CD28
2
CD57
1 T cells
Variable Median IQR P Median IQR P Median IQR P Median IQR P
Age, years 40–44 7.5 8.9 .85 27.5 25.5 .61 2.9 5.4 .97 34.6 21.6 .83
45–49 7.7 10.6 27.5 17.7 2.4 6.0 36.7 18.9
>50 9.7 10.9 31.8 20.1 1.9 5.2 36.9 18.7
CD4
1 T cell count, cells/lL ,200 19.4 15.8 <.01 33.9 26.6 <.01 3.6 15.0 .52 37.7 21.2 .40
200–349 10.4 8.7 37.6 21.2 3.1 6.3 37.1 16.2
350–499 6.1 3.2 27.4 23.9 2.0 4.2 33.5 21.9
>500 4.6 3.1 20.6 19.2 2.4 5.6 31.3 22.5
CD4/CD8 ratio <1 9.5 10.1 <.01 32.3 23.1 <.01 2.7 6.0 .37 36.8 20.2 .11
.1 3.7 2.2 14.7 11.8 1.6 4.3 29.0 17.7
Prior visits with HIV RNA level of .4000 copies/mL
a <6 5.7 6.0 <.01 24.3 22.6 .08 3.3 5.6 .30 35.4 19.4 .74
.6 11.2 9.7 32.3 20.2 2.0 6.3 36.3 23.3
HIV RNA, copies/mL <4000 9.0 9.4 <.01 25.5 14.7 <.01 5.4 6.7 .56 35.6 14.6 .98
4000–60,000 14.6 10.3 38.5 16.6 8.9 16.6 35.4 14.0
>60,000 17.7 13.7 40.7 17.5 3.4 3.7 34.3 12.4
PI use
a Never 8.6 8.5 .40 33.5 21.3 .18 3.3 5.0 .81 38.3 15.9 .51
<3.3 years 7.7 15.3 26.4 23.3 2.1 7.2 33.1 18.4
.3.3 years 7.3 7.9 27.1 23.9 2.9 6.3 33.5 27.1
NRTI use
a Never 6.6 5.8 .46 29.9 10.9 .52 4.5 5.3 .63 42.8 20.8 .62
<6.1 years 9.4 14.7 32.4 33.8 2.3 6.7 36.6 16.8
.6.1 years 7.3 7.5 27.1 24.4 2.6 6.2 33.6 25.2
NNRTI use
a Never 7.3 7.0 .47 29.3 20.8 .93 3.3 6.7 .42 33.5 20.8 .87
<1.9 years 9.5 10.4 27.1 16.0 2.3 4.2 37.4 23.3
.1.9 years 7.1 8.3 29.6 32.3 2.2 5.1 35.5 18.4
Abacavir use Yes 8.1 7.3 .99 27.1 20.9 .31 2.1 4.4 .24 30.7 23.4 .54
No 7.4 10.6 30.2 23.5 2.6 5.9 36.6 21.7
Adherence to antiretroviral medications Yes 6.9 8.2 .06 22.6 26.8 .45 2.3 5.9 .73 32.8 15.8 .28
No 11.6 7.8 29.3 14.8 2.9 5.0 42.5 23.4
Race/ethnicity African American 4.0 4.2 .01 24.8 15.8 .03 .6 4.6 .05 38.6 16.5 .02
Hispanic 9.5 13.1 36.7 29.3 3.8 8.4 38.4 17.3
White or other 7.8 8.6 28.9 21.7 2.0 6.1 31.9 19.1
Smoking Current 7.5 9.1 .79 27.4 19.1 .54 2.1 5.9 .22 31.8 17.8 <.01
Past 7.9 10.0 32.8 27.3 4.0 5.0 40.6 19.7
Never 7.5 10.4 24.9 31.6 1.5 6.3 35.8 20.7
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.Table 2. (Continued)
Percentage of CD4
1
CD38
1DR
1 T cells
Percentage of CD8
1
CD38
1DR
1 T cells
Percentage of CD4
1CD28
2
CD57
1 T cells
Percentage of CD8
1CD28
2
CD57
1 T cells
Variable Median IQR P Median IQR P Median IQR P Median IQR P
Hepatitis C Yes 7.5 8.5 .99 28.2 17.0 .61 2.0 5.1 .23 36.8 23.6 .87
No 7.9 11.3 30.9 30.0 3.1 6.6 35.5 19.4
Hypertension Yes 7.5 12.1 .24 27.6 26.2 .86 2.0 4.8 .88 37.3 24.5 .71
No 7.9 7.6 30.3 22.2 2.8 6.7 34.3 17.0
Diabetes Yes 7.7 10.4 .43 23.2 15.0 .13 1.6 6.0 .37 33.6 18.7 .32
No 7.4 8.9 30.2 23.7 2.4 5.7 35.6 21.6
BMI ,25 7.5 6.9 .20 30.3 24.1 .41 2.8 6.2 .25 32.3 19.6 .66
25–30 9.8 10.8 28.1 22.3 1.9 4.3 36.8 24.7
.30 6.4 9.7 27.6 28.6 4.7 6.5 37.2 15.2
Diabetes medication use Yes 13.2 18.4 .35 26.1 21.8 .79 4.3 8.3 .99 31.1 28.5 .75
No 7.7 9.0 29.3 26.0 2.4 5.9 36.0 21.1
Lipid-lowering drug use Yes 6.2 6.2 .07 19.7 18.8 .08 6.7 2.9 .05 33.9 11.2 .70
No 7.9 10.6 29.1 23.2 2.3 5.6 36.3 22.9
Family History of CAD Yes 7.3 8.4 .69 29.5 15.3 .70 1.9 5.6 .87 43.2 15.5 .13
No 7.9 9.2 28.2 21.9 2.7 6.3 33.5 19.6
HDL-C level, mg/dL ,40 9.6 10.4 .07 36.7 28.1 <.01 1.6 4.9 .09 38.4 21.4 .03
>40 6.2 8.6 25.7 22.2 3.5 6.2 32.6 19.6
LDL-C level, mg/dL <160 7.4 10.7 .87 29.1 24.3 .17 2.6 5.9 .69 36.3 21.6 .33
.160 9.5 7.8 12.8 24.6 2.3 8.2 31.1 28.3
Weight, kg
a <73 9.0 12.0 .24 30.3 24.5 .10 2.0 5.0 .05 34.3 25.4 .52
.73 6.5 9.2 27.4 21.3 3.3 6.1 37.2 17.9
NOTE. P values were derived using the (nonparametric) Wilcoxon and Kruskal-Wallis tests. BMI, body mass index; CAD, coronary artery disease; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range;
LDL-C, low-density lipoprotein cholesterol; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a Values presented represent those above or below the median value. For use of antiretroviral medication, categories were deﬁned as never and 2 categories of ever use with total observed duration of use either below
or above the median duration in the drug user group.
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9lesions. When mutually adjusted in the same model, the prev-
alence ratiolesions for each SD change in the percentage of
CD8
1CD38
1HLA-DR
1 T cells was 1.9 (95% CI, 1.1–3.2; P 5
.02), and the prevalence ratiolesions for each SD change in the
percentage of CD8
1CD28
2CD57
1 T cells was 1.6 (95% CI, .9–
2.8; P 5 .09).
We also examined CD4
1 and CD8
1 T cell activation simul-
taneously in relation to carotid lesions. When entered into
Figure 3. T-cell activation (CD38
1HLA-DR
1) and senescence (CD28
2CD57
1) in relation to carotid lesions. Among human immunodeficiency virus
(HIV)–infected women, higher CD4
1CD38
1HLA-DR
1 T cell frequency (P 5 .02) and higher CD8
1CD38
1HLA-DR
1 T cell frequency (P 5 .04) were
observed among 19 women with carotid lesions than among 96 women without carotid lesions. Similarly, among HIV-infected women,
CD8
1CD28
2CD57
1 T cell frequency was higher among those with carotid lesions than among those without carotid lesions (P 5 .03). No significant
difference in CD4
1CD28
2CD57
1 Tcell frequency was observed in comparing HIV-infected women with and without lesions. Among 43 HIV-uninfected
women, none of these T cell parameters differed according to the presence or absence of carotid lesions. P values were computed using the Kruskal-
Wallis test.
Table 3. Multivariate Associations of T Cell Activation and Senescence Markers With Subclinical Carotid Artery Disease Among
Women With Human Immunodeficiency Virus (HIV) Infection
Adjusted for age and current use of antiretroviral medications Also adjusted for HIV RNA level
Variable
Effect
estimate
95% conﬁdence
interval P
Effect
estimate
95% conﬁdence
interval P
PRlesions for each SD increase
in T cell marker
CD4
1CD38
1HLA-DR
1 T cells 1.6 1.1–2.2 .02 1.6 1.1–2.3 .02
CD8
1CD38
1HLA-DR
1 T cells 2.0 1.2–3.3 <.01 2.0 1.2–3.3 <.01
CD4
1CD28
2CD57
1 T cells 1.1 .8–1.6 .64 1.1 .8–1.6 .61
CD8
1CD28
2CD57
1 T cells 1.9 1.1–3.1 .01 1.9 1.1–3.1 .01
Increase in cIMT for each SD
increase in T cell marker
CD4
1CD38
1HLA-DR
1 T cells .001 2.019 to .019 .96 .001 2.019 to .021 .92
CD8
1CD38
1HLA-DR
1 T cells 2.002 2.022 to .018 .81 2.002 2.023 to .019 .85
CD4
1CD28
2CD57
1 T cells .003 2.016 to .022 .74 .003 2.017 to .024 .74
CD8
1CD28
2CD57
1 T cells 2.006 2.026 to .014 .57 2.006 2.027 to .015 .58
NOTE. Measures of T cell activation and T cell senescence were log-transformed. The text describes results after adjustment for CD4
1 T cell count and ratio of
CD4
1 T cells to CD8
1 T-cells. Additional adjustment for participant characteristics described in Table 1 did not change the results substantially. cIMT, carotid intima-
media thickness of the right common carotid artery; PRlesions, prevalence ratio for carotid lesions.
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1 T cell activation remained signiﬁcantly
associated with prevalence of carotid lesions (prevalence
ratiolesions, 1.8; 95% CI, 1.0–3.3; P 5 .05), whereas CD4
1 Tc e l l
activation did not (prevalence ratiolesions, 1.2; 95% CI, .7–1.8;
P 5 .54).
DISCUSSION
HIV-infected individuals have an increased risk of CVD, and
effective HIV therapy appears to improve CVD risk. We report
several ﬁndings that suggest possible explanatory mechanisms
for the association between HIV infection and vascular disease.
First, consistent with prior data [6], HIV infection was associ-
ated with markedly elevated levels of activated (CD38
1HLA-
DR
1) peripheral T cells. Viremic suppression through effective
antiretroviral therapy appeared to reduce but not completely
reverse this process. Second, among HIV-infected women, T cell
activation was associated with markers of subclinical carotid
artery disease after adjustment for multiple confounders. Third,
CD8
1 T cell senescence (phenotypically deﬁned by absence of
CD28 and presence of CD57) was also elevated in women with
HIV disease, and the frequency of these cells was associated with
subclinical carotid artery disease among HIV-infected women.
Finally, these associations of T cell activation and senescence
with carotid artery parameters were not observed in a pop-
ulation of HIV-uninfected controls who were studied using
identical methods and who had comparable cardiovascular risk
factor proﬁles. Collectively, these observations are consistent
with a model in which HIV infection results in immune acti-
vation, acceleratedimmunologic aging, and the premature onset
of CVD. Effective HIV treatment reduces but may not fully
reverse this process.
The ultrasound protocol used in this study was designed to
capture several different carotid artery parameters.Among HIV-
infectedwomen,Tcellactivationandsenescencewereassociated
with the presence of carotid lesions, deﬁned as focal thickening
(.1.5 mm) of the intima-media layer. These lesions typically
form at branch points in the internal carotid artery and the
carotid bifurcation, where turbulent blood ﬂow evokes elabo-
ration of vascular cellular adhesion molecule-1 and other in-
ﬂammatory mediators [13]. In contrast, we found no
association between T cell activation and mean cIMT of the
common carotid artery, a region that is not prone to the de-
velopment of symptomatic lesions. Longitudinal data show that
commoncarotidarterywallthicknessprogressesmorerapidlyin
patients with HIV infection who have poor viral control [14],
although some prior studies have shown a stronger association
of HIV disease with lesions in the internal carotid artery and
carotid bifurcation than with common carotid artery thickness
[15]. We speculate on potential explanations for these ob-
servations. Because of regional hemodynamics, the internal and
bifurcation regions of the carotid may be more prone to the
development of inﬂammation-related vascular lesions. Patients
with other inﬂammatory conditions such as rheumatoid ar-
thritis and systemic lupus erythematosus also appear to have
normal common carotid cIMT but increased prevalence of ca-
rotid artery lesions [16, 17]. Alternatively, localized infection of
vascular tissues by HIV [18] or other pathogens might produce
focal lesions in the absence of generalized carotid artery wall
thickening. It remains unclear whether the observed differences
across carotid segments are biologically important or due to
technical aspects of our cross-sectional imaging protocol.
Although we lacked data on the coronary vasculature, a recent
report demonstrated a high prevalence of obstructive coronary
artery lesions among HIV-infected adults (6.5% vs 0% in con-
trols) who had no known history or symptoms of coronary
disease [19].
Multivariate analyses appeared to suggest that CD8
1 Tc e l l
activation had the more robust association with carotid lesions
when both CD4
1 and CD8
1 T cell activation were modeled
simultaneously. Mouse models of atherosclerosis (eg, low-
density lipoprotein receptor knockout [LDLR
2/2]m i c ea n d
apolipoprotein E knockout [ApoE
2/2] mice) have more clearly
implicated CD4
1 T cells than CD8
1 T cells in atherogenesis [8].
However, as recently hypothesized by Andersson and colleagues
[8], CD8
1 T cells may become atherogenic in response to in-
tracellular infections even if they are not involved in athero-
genesis in normal circumstances. Notably, comparisons of our
HIV-infected women with an HIV-uninfected control group
suggested a weaker or null association of T cell activation with
subclinicalcarotidarterydiseaseinthe absenceofHIV infection.
Thismaysuggest that direct vasculareffectsofpathogensaffecting
HIV-infected individuals, or perhaps HIV itself, contributed to
the association of immune activation with subclinical carotid
artery disease in the HIV-infected group. Alternatively, the lack of
signiﬁcant ﬁndings in the HIV-uninfected controls may reﬂect
a threshold of immune activation that is required to demonstrate
an association with carotid wall thickness. It should be noted that
although the percentage of activated CD4 cells was increased
among patients with HIV infection, the absolute number of pe-
ripheral T cells may be reduced in HIV infection, and moreover,
these measurements only reﬂect cells circulating in blood [20].
The mechanism whereby HIV causes increased inﬂammation
and T cell activation is an active area of investigation and has
important clinical implications for preventing HIV-related in-
fectious and noninfectious (eg, cardiovascular) morbidity. The
degree of inﬂammation and immune activation is thought to be
too high to be simply due to expansion of HIV-speciﬁc T cells.
HIV infected persons are often co-infected with other patho-
gens, including CMV and the hepatitis viruses. Recent work by
our group suggests that CMV may be an important cause of
T cell changes in HIV disease, which is of interest given our
previous ﬁndings that high levels of CMV-speciﬁc T cells are
associated with increased cIMT [21]. HIV infection results in
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increased translocation of microbial products from the gut lu-
men into the systemic circulation. These changes may increase
immune activation and potentially trigger inﬂammatory and
procoagulant mechanisms that increase vascular risk [22]. Finally,
irreversible changes in the lymphoid infrastructure—including
collagen deposition in lymphatic tissues and loss of thymic
function—may also contribute to the inﬂammatory environment
that exists in HIV disease [23].
Immunosenescence is deﬁned as the gradual age-related de-
cline in immune function that contributes to vaccine un-
responsiveness and other sequelae among the elderly. Although
multiple perturbations to the adaptive and nonadaptive im-
mune system have been reported, the strongest and most con-
sistent correlates of immunosenescence include the oligoclonal
expansion of memory effector CD8
1CD28
2 Tc e l l sa n dt h e
expansion of CD57-expressing CD8
1 T cells. These CD28
2 cells
have limited ability to proliferate and are apoptosis-resistant
[24]. Similar observations are emerging with regard to CD4
1
T cells, which also appear to become more oligoclonal and less
functional with age, particularly among CMV seropositive per-
sons [9]. As shown elsewhere and conﬁrmed here, untreated
HIV infection appears to result in expansion of phenotypically
deﬁned immunosenescent T cells. Importantly, we also show
that the process of CD8
1 T cell immunosenescence is not re-
versed by effective antiretroviral therapy. We further showed
that HIV-associated changes in the immunosenescent proﬁle of
circulating T cells predicted increased frequency of carotid
lesions. This is a novel ﬁnding that is consistent with a growing
body of evidence. Enriched numbers of CD28
2 Tc e l l sa r ef o u n d
in atherosclerotic plaques [25]. In patients with coronary dis-
ease, CMV infection contributes to loss of CD28 and telomeric
shortening in CD8
1 T cells, which in turn predicts cardiac
dysfunction[11].CD4
1CD28
2Tcellsthatrecognizeheat-shock
protein 60, an antigen that triggers atherosclerosis in animal
models, have been implicated in severity and prognosis of cor-
onary disease [26, 27]. However, the present study of HIV-
infected women implicated CD8
1 T cell senescence but not
CD4
1 T cell senescence in subclinical atherosclerosis. Our data
support the emerging hypothesis that T cell subsets expressing
markers of immunosenescence and terminal differentiation may
be CVD mediators.
Limitations of the present study include its observational
study design and the measurement of immune activation and
senescence at a single study visit. Use of HIV medications was
not guided by our research protocol. However, we were able to
control for detailed, prospectively collected longitudinal in-
formation on medication history [12]. The HIV-uninfected
control group was relatively modest in size. Information on
duration of HIV infection was lacking. We did not measure
serum biomarkers of inﬂammatory mediators such as in-
terleukin6,althoughwepreviouslyreportedaspartoftheWIHS
that C-reactive protein did not predict carotid atherosclerosis
among HIV-infected womenindependently of other clinical risk
factors [28]. Although the measures of subclinical vascular dis-
ease used in this investigation predict incident CVD events in
the general population, no studies have validated this assump-
tion in the HIV-infected population, and too few events are
available in our cohort to test this assumption.
In conclusion, our data provide further evidence that per-
sistent activation of the immune system is associated with vas-
cular abnormalities among HIV-infected individuals. This
relationship was suggested by a small prior study that, unlike the
present investigation, did not feature multivariate analyses, did
not control for potential confounding effectsof HIV-related and
CVD-related variables, and lacked an HIV-uninfected control
group [29]. These results have important implications for as-
sessment of vascular risk among adults with HIV infection.
Additional research is needed to identify the events or exposures
in HIV-infected adults that may drive T cell activation and se-
nescence (including immuneresponses toHIV,co-infections,or
bacterial translocation) and, in turn, increase vascular risk.
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